Age-related macular degeneration therapeutic - BiophytisAlternative Names: BIO 201; MACUNEOS
Latest Information Update: 01 Jul 2016
At a glance
- Originator Biophytis
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Age-related macular degeneration
Most Recent Events
- 01 Jul 2016 Clinical trials in Age-related macular degeneration (In volunteers, In the elderly) in France (PO)